213 related articles for article (PubMed ID: 28473314)
1. Combined Anti-VEGF and Anti-CTLA-4 Therapy Elicits Humoral Immunity to Galectin-1 Which Is Associated with Favorable Clinical Outcomes.
Wu X; Li J; Connolly EM; Liao X; Ouyang J; Giobbie-Hurder A; Lawrence D; McDermott D; Murphy G; Zhou J; Piesche M; Dranoff G; Rodig S; Shipp M; Hodi FS
Cancer Immunol Res; 2017 Jun; 5(6):446-454. PubMed ID: 28473314
[TBL] [Abstract][Full Text] [Related]
2. VEGF Neutralization Plus CTLA-4 Blockade Alters Soluble and Cellular Factors Associated with Enhancing Lymphocyte Infiltration and Humoral Recognition in Melanoma.
Wu X; Giobbie-Hurder A; Liao X; Lawrence D; McDermott D; Zhou J; Rodig S; Hodi FS
Cancer Immunol Res; 2016 Oct; 4(10):858-868. PubMed ID: 27549123
[TBL] [Abstract][Full Text] [Related]
3. Angiopoietin-2 as a Biomarker and Target for Immune Checkpoint Therapy.
Wu X; Giobbie-Hurder A; Liao X; Connelly C; Connolly EM; Li J; Manos MP; Lawrence D; McDermott D; Severgnini M; Zhou J; Gjini E; Lako A; Lipschitz M; Pak CJ; Abdelrahman S; Rodig S; Hodi FS
Cancer Immunol Res; 2017 Jan; 5(1):17-28. PubMed ID: 28003187
[TBL] [Abstract][Full Text] [Related]
4. Anti-CTLA-4 based therapy elicits humoral immunity to galectin-3 in patients with metastatic melanoma.
Wu X; Giobbie-Hurder A; Connolly EM; Li J; Liao X; Severgnini M; Zhou J; Rodig S; Hodi FS
Oncoimmunology; 2018; 7(7):e1440930. PubMed ID: 29900046
[TBL] [Abstract][Full Text] [Related]
5. Influence of ipilimumab on expanded tumour derived T cells from patients with metastatic melanoma.
Bjoern J; Lyngaa R; Andersen R; Hölmich LR; Hadrup SR; Donia M; Svane IM
Oncotarget; 2017 Apr; 8(16):27062-27074. PubMed ID: 28423678
[TBL] [Abstract][Full Text] [Related]
6. Robust Antitumor Responses Result from Local Chemotherapy and CTLA-4 Blockade.
Ariyan CE; Brady MS; Siegelbaum RH; Hu J; Bello DM; Rand J; Fisher C; Lefkowitz RA; Panageas KS; Pulitzer M; Vignali M; Emerson R; Tipton C; Robins H; Merghoub T; Yuan J; Jungbluth A; Blando J; Sharma P; Rudensky AY; Wolchok JD; Allison JP
Cancer Immunol Res; 2018 Feb; 6(2):189-200. PubMed ID: 29339377
[TBL] [Abstract][Full Text] [Related]
7. Bevacizumab plus ipilimumab in patients with metastatic melanoma.
Hodi FS; Lawrence D; Lezcano C; Wu X; Zhou J; Sasada T; Zeng W; Giobbie-Hurder A; Atkins MB; Ibrahim N; Friedlander P; Flaherty KT; Murphy GF; Rodig S; Velazquez EF; Mihm MC; Russell S; DiPiro PJ; Yap JT; Ramaiya N; Van den Abbeele AD; Gargano M; McDermott D
Cancer Immunol Res; 2014 Jul; 2(7):632-42. PubMed ID: 24838938
[TBL] [Abstract][Full Text] [Related]
8. Structural basis for cancer immunotherapy by the first-in-class checkpoint inhibitor ipilimumab.
Ramagopal UA; Liu W; Garrett-Thomson SC; Bonanno JB; Yan Q; Srinivasan M; Wong SC; Bell A; Mankikar S; Rangan VS; Deshpande S; Korman AJ; Almo SC
Proc Natl Acad Sci U S A; 2017 May; 114(21):E4223-E4232. PubMed ID: 28484017
[TBL] [Abstract][Full Text] [Related]
9. Immunomodulating antibodies in the treatment of metastatic melanoma: the experience with anti-CTLA-4, anti-CD137, and anti-PD1.
Simeone E; Ascierto PA
J Immunotoxicol; 2012; 9(3):241-7. PubMed ID: 22524673
[TBL] [Abstract][Full Text] [Related]
10. Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition.
Heppt MV; Heinzerling L; Kähler KC; Forschner A; Kirchberger MC; Loquai C; Meissner M; Meier F; Terheyden P; Schell B; Herbst R; Göppner D; Kiecker F; Rafei-Shamsabadi D; Haferkamp S; Huber MA; Utikal J; Ziemer M; Bumeder I; Pfeiffer C; Schäd SG; Schmid-Tannwald C; Tietze JK; Eigentler TK; Berking C
Eur J Cancer; 2017 Sep; 82():56-65. PubMed ID: 28648699
[TBL] [Abstract][Full Text] [Related]
11. Combined immune checkpoint blockade (anti-PD-1/anti-CTLA-4): Evaluation and management of adverse drug reactions.
Hassel JC; Heinzerling L; Aberle J; Bähr O; Eigentler TK; Grimm MO; Grünwald V; Leipe J; Reinmuth N; Tietze JK; Trojan J; Zimmer L; Gutzmer R
Cancer Treat Rev; 2017 Jun; 57():36-49. PubMed ID: 28550712
[TBL] [Abstract][Full Text] [Related]
12. Circulating galectin-1 delineates response to bevacizumab in melanoma patients and reprograms endothelial cell biology.
Bannoud N; Stupirski JC; Cagnoni AJ; Hockl PF; Pérez Sáez JM; García PA; Mahmoud YD; Gambarte Tudela J; Scheidegger MA; Marshall A; Corrie PG; Middleton MR; Mariño KV; Girotti MR; Croci DO; Rabinovich GA
Proc Natl Acad Sci U S A; 2023 Jan; 120(3):e2214350120. PubMed ID: 36634146
[TBL] [Abstract][Full Text] [Related]
13. Ipilimumab (Yervoy) and the TGN1412 catastrophe.
Bakacs T; Mehrishi JN; Moss RW
Immunobiology; 2012 Jun; 217(6):583-9. PubMed ID: 21821307
[TBL] [Abstract][Full Text] [Related]
14. Ipilimumab Combined with Nivolumab: A Standard of Care for the Treatment of Advanced Melanoma?
Carlino MS; Long GV
Clin Cancer Res; 2016 Aug; 22(16):3992-8. PubMed ID: 27340279
[TBL] [Abstract][Full Text] [Related]
15. CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients.
Ott PA; Hodi FS; Robert C
Clin Cancer Res; 2013 Oct; 19(19):5300-9. PubMed ID: 24089443
[TBL] [Abstract][Full Text] [Related]
16. Ctla-4 blockade plus adoptive T-cell transfer promotes optimal melanoma immunity in mice.
Mahvi DA; Meyers JV; Tatar AJ; Contreras A; Suresh M; Leverson GE; Sen S; Cho CS
J Immunother; 2015; 38(2):54-61. PubMed ID: 25658614
[TBL] [Abstract][Full Text] [Related]
17. Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma.
Wallin JJ; Bendell JC; Funke R; Sznol M; Korski K; Jones S; Hernandez G; Mier J; He X; Hodi FS; Denker M; Leveque V; Cañamero M; Babitski G; Koeppen H; Ziai J; Sharma N; Gaire F; Chen DS; Waterkamp D; Hegde PS; McDermott DF
Nat Commun; 2016 Aug; 7():12624. PubMed ID: 27571927
[TBL] [Abstract][Full Text] [Related]
18. Ipilimumab: a novel immunostimulatory monoclonal antibody for the treatment of cancer.
Graziani G; Tentori L; Navarra P
Pharmacol Res; 2012 Jan; 65(1):9-22. PubMed ID: 21930211
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases.
Di Giacomo AM; Danielli R; Guidoboni M; Calabrò L; Carlucci D; Miracco C; Volterrani L; Mazzei MA; Biagioli M; Altomonte M; Maio M
Cancer Immunol Immunother; 2009 Aug; 58(8):1297-306. PubMed ID: 19139884
[TBL] [Abstract][Full Text] [Related]
20. The antitumor immunity of ipilimumab: (T-cell) memories to last a lifetime?
Postow MA; Callahan MK; Wolchok JD
Clin Cancer Res; 2012 Apr; 18(7):1821-3. PubMed ID: 22338019
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
